Skip to main content
Premium Trial:

Request an Annual Quote

So Close to Free

Russ Altman writes that with all the competition in the genome sequencing space, particularly with Complete Genomics' recent announcement, researchers be able to get their "entire genome sequence basically for free." He says this will have an impact on medicine, particularly pharmacogenomics and predictive diagnostics. Altman also worries that the current methods of trying to protect consumers by relying on government regulations or requiring a physician will not work. "We must work to educate every day people about how to interpret their genome and how to use the information beneficially," Altman writes.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.